Abstract:Advanced age is strikingly linked to increased incidence of cancer. To gain insight into the mechanism underlying the association between increased cancer incidence and aging in normal human physiological conditions, we used a case-control design and measured the mRNA expression levels of p53, ATM, hTERT and TRF2, the four major protectors of genomic integrity, in isolated peripheral blood lymphocytes from 202 confirmed bladder cancer (BC) patients and 199 healthy controls. Significant age effects on expression levels were observed. When we divided the study subjects into three age groups (< 57, 57-65 and >= 65), the expressions of p53, ATM and TRF2 significantly decreased with advancing age in cases (P for trend <= 0.001, 0.01 and 0.01 for p53, ATM and TRF2, respectively). In controls, however, p53 expression significantly increased with advancing age (P for trend = 0.05). Among subjects >= 65 years of age, the expressions of p53, ATM and TRF2 were significantly lower in cases than in controls (P = 0.003, 0.04 and 0.05 for p53, ATM and TRF2, respectively), suggesting that attenuated genomic maintenance mechanisms lead to increased cancer risk in older individuals. When we dichotomized our study population at the median age of study subjects (61 years old), low p53 expression was associated with a significantly increased BC risk in older people (OR = 2.27, 95% CI = 1.00-5.16). In addition, older subjects without detectable hTERT expression had a significantly reduced BC risk (OR = 0.41, 95% CI = 0.17-0.99). Our study provides the first epidemiologic evidence that the increased genomic instability resulting from the combination of telomere dysfunction, impaired ATM- and p53-mediated DNA damage, and/or telomere dysfunction response pathway contributes to increased cancer incidence in the elderly population.

Longevity, stress response, and cancer in aging telomerase-deficient mice

Mouse Model: Telomeres and Telomerase in Stem Cell and Cancer

Telomere function and regulation from mouse models to human ageing and disease

Telomere length, stem cells and aging

Telomeric epigenetic response mediated by Gadd45a regulates stem cell aging and lifespan.

The mTOR pathway is necessary for survival of mice with short telomeres

Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer.

Telomeres and telomerase in stem cells during aging and disease.

Proteins Induced by Telomere Dysfunction and DNA Damage Represent Biomarkers of Human Aging and Disease

Genetic dissection of the mechanisms underlying telomere-associated diseases: impact of the TRF2 telomeric protein on mouse epidermal stem cells

Essential role of limiting telomeres in the pathogenesis of Werner syndrome

Senescence Reprogramming by MTHFD2 Deficiency Facilitates Tumor Progression

Telomeres, aging and cancer: In search of a happy ending

p21 deletion rescues stem cell senescence and premature ageing of telomere dysfunctional mice without accelerating cancer formation

Telomere Dysfunction Induces Environmental Alterations Limiting Hematopoietic Stem Cell Function and Engraftment

Telomere shortening and ageing

Alterations of the Systemic Environment Are the Primary Cause of Impaired B and T Lymphopoiesis in Telomere-Dysfunctional Mice.

The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo.

Roles of tumor suppressor and telomere maintenance genes in cancer and aging--an epidemiological study.

Cell intrinsic and extrinsic mechanisms of stem cell aging depend on telomere status.

Loss of Telomere Protection: Consequences and Opportunities